Sucht-Zeitschrift für Wissenschaft und Praxis, published by HOGREFE AG in Switzerland, is a pivotal journal addressing the interrelated fields of addiction science and mental health. With an ISSN of 0939-5911 and an E-ISSN of 1664-2856, this journal has been dedicated to fostering interdisciplinary research and practical applications since its inception in 1991, continuing through to 2024. As a respected source in the field, it holds a 2023 Q3 quartile ranking in Medicine (miscellaneous), a Q4 ranking in Psychiatry and Mental Health, and a Q3 ranking in Public Health, highlighting its broad relevance and growing impact on contemporary health discussions. While currently not offering open access options, the journal provides a rich platform for researchers, practitioners, and students to share and gain insights into innovative practices and scientific findings that advance the understanding of addiction and its societal implications. With its contributions indexed in Scopus and a variety of rankings reflective of its quality, Sucht-Zeitschrift für Wissenschaft und Praxis serves as an essential resource for those committed to advancing knowledge and practice in addiction-related fields.

Substance Abuse Treatment, Prevention, and Policy is a premier open access journal published by BMC, dedicated to advancing the understanding and improvement of substance abuse treatment and prevention strategies. Since its inception in 2006, this journal has established itself as a significant resource in the fields of Health Policy and Psychiatry and Mental Health, proudly maintaining a strong reputation reflected in its 2023 Scopus rankings, which place it in the top quartiles of these categories. With an impactful focus on policy implications and evidence-based practices, the journal's comprehensive coverage supports the sharing of innovative research and perspectives aimed at mitigating substance abuse challenges worldwide. Open access since its launch, it ensures that vital research is readily available to researchers, practitioners, and students alike, facilitating collaboration and discourse in this critical area of public health. Its commitment to high-quality research is underscored by its rankings within the 78th percentile for Health Policy and 66th percentile for Psychiatry and Mental Health, highlighting its influence and relevance in addressing pressing issues in substance misuse.

JOURNAL OF PSYCHOACTIVE DRUGS, published by Routledge Journals, Taylor & Francis Ltd, stands as a leading resource in the fields of psychology and medicine, focusing on the intersection of psychoactive substances and their impact on human behavior. With an ISSN of 0279-1072 and E-ISSN 2159-9777, this esteemed journal has been a pivotal platform for rigorous research since its inception in 1967, contributing to the understanding of drug use, its societal implications, and therapeutic potentials. It currently holds a Q2 ranking in both the miscellaneous categories of Medicine and Psychology for 2023, reflecting its significant standing within academic circles. Moreover, its Scopus rankings place it at the 49th percentile in General Psychology and 101st in Medicine, underscoring its relevance in contemporary research. Although it is not available via Open Access, the journal maintains a commitment to advancing knowledge through its annual publications until 2024. JOURNAL OF PSYCHOACTIVE DRUGS is essential for researchers, professionals, and students seeking to explore the complexities of psychoactive substances and their effects in various contexts.

Substance Abuse is a premier scholarly journal published by SAGE Publications Inc, dedicated to advancing the understanding and treatment of substance use disorders. With an established presence from 1995 to 2023, the journal boasts an impressive Q1 ranking in both Medicine (miscellaneous) and Psychiatry and Mental Health, positioning it among the top tier of academic publications in these fields. Researchers and professionals will find its articles, which are grounded in rigorous empirical studies and innovative interventions, essential for addressing the complex and multifaceted nature of substance abuse. Although not an open access publication, Substance Abuse maintains a commitment to sharing valuable insights and findings, making it a vital resource for those looking to enhance their knowledge and practice. Located in Thousand Oaks, CA, this journal serves as a critical forum for international dialogue and research dissemination, ensuring that current trends and challenges in substance use are thoughtfully examined and discussed within the academic community.

Suchttherapie, an esteemed journal published by GEORG THIEME VERLAG KG, serves as a critical platform within the fields of Applied Psychology and Psychiatry and Mental Health. Established in 2000 and continuing through 2024, this journal is committed to advancing the understanding and treatment of addiction and related psychological issues. Although it currently stands in the Q4 Quartile ranking and is categorized as low percentile in both Scopus Ranks and impact metrics, its significance lies in its dedication to disseminating cutting-edge research and clinical findings that contribute to the evolving landscape of therapeutic practices. Published in Germany, the journal facilitates unlimited access to the vital discourse surrounding mental health and addiction treatment, making it a valuable resource for researchers, professionals, and students alike seeking to enhance their knowledge and skills in this important area of study. As the field continues to grow, Suchttherapie plays a pivotal role in bridging practice with academic rigor, ensuring that readers remain informed on the latest methodologies and insights.

Addiction Science & Clinical Practice is a premier open-access journal dedicated to advancing the understanding and treatment of addiction through evidence-based research and clinical practice. Published by BMC in the United Kingdom since 2007, this journal has significantly impacted the fields of Clinical Psychology, Medicine, and Psychiatry and Mental Health, proudly securing a Q1 ranking in multiple categories as of 2023. With an emphasis on high-quality research, the journal provides an inclusive platform for the dissemination of innovative findings and clinical insights that address the complexities of addiction. Researchers, practitioners, and students alike benefit from its unrestricted access since 2012, allowing for widespread dissemination of knowledge. Located at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to lead the way in fostering collaboration and informing best practices in addiction science.

JOURNAL OF ADDICTIVE DISEASES, published by ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, serves as a pivotal platform for researchers, clinicians, and students in the realms of clinical psychology, psychiatry, and addiction studies. With a distinguished history dating back to its inception in 1991, this journal spans critical research developments with its current scope covering converged years from 2018 to 2024, ensuring a robust repository of knowledge. Notably, it holds a respectable impact factor and is categorized in Q2 quartiles across several disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health for 2023, reflecting its impactful contributions to the scientific community. Despite the journal not currently offering Open Access, it remains highly ranked, occupying positions in the top percentiles of Scopus rankings. This journal emphasizes the importance of disseminating high-quality research focused on addictive behaviors and diseases, thereby addressing vital clinical and public health challenges.

The Journal of Social Work Practice in the Addictions is a pivotal publication in the field of social work, dedicated to addressing the multifaceted challenges of addiction through rigorous research and practice. Published by Routledge Journals, Taylor & Francis Ltd, this journal has been a valuable resource since its inception in 2001 and continues to provide vital insights as it converges towards 2024. With a focus on empirical studies, theoretical advancements, and innovative practice approaches, it serves professionals and researchers alike who are engaged in the health and social sciences. Holding a respectable Q3 quartile ranking in both Health (Social Science) and Rehabilitation and a Q4 ranking in Social Work, it emphasizes the importance of interdisciplinary collaboration in tackling issues of addiction. The journal does not currently offer open access, ensuring exclusive dissemination to its dedicated readership, which includes practitioners, scholars, and students committed to improving outcomes for individuals affected by substance use disorders. As an essential platform within the community, it fosters knowledge exchange and supports evidence-based practice, thereby enhancing the field’s collective understanding of addiction-related challenges.

Annals of Clinical Psychiatry, published by QUADRANT HEALTHCOM INC, is a leading journal in the fields of Medicine and Psychiatry & Mental Health. With its longstanding commitment to advancing clinical knowledge since 1989, this esteemed journal contributes invaluable insights into current psychiatric practices and mental health research. The journal is recognized in the Scopus ranking with a position in the 34th percentile, reflective of its focused scope and substantial academic contributions. While access to the journal is tailored for professionals and researchers, the absence of Open Access highlights the journal's dedication to maintaining quality and rigorous peer-reviewed standards. As part of the Q3 quartile for both Medicine and Psychiatry categories in 2023, Annals of Clinical Psychiatry serves as an essential resource for those dedicated to improving mental health outcomes, making it a vital platform for practitioners, researchers, and students alike. Situated in Parsippany, New Jersey, the journal remains a pivotal entity that fosters scholarly dialogue and exploration in clinical psychiatry.

The Journal of Dual Diagnosis, published by Routledge Journals, Taylor & Francis Ltd, is a leading interdisciplinary platform dedicated to the critical study of co-occurring mental health and substance use disorders. With its ISSN 1550-4263 and E-ISSN 1550-4271, this esteemed journal has been at the forefront of advancing research and clinical practice since its inception in 2004, and continues to serve as a vital resource until 2024. Ranked in the second quartile (Q2) in Psychiatry and Mental Health and positioned at the 64th percentile in the Scopus rankings, it emphasizes the importance of integrating care across various domains of health. Although not open access, it offers a wealth of peer-reviewed articles, case studies, and reviews suitable for researchers, practitioners, and students alike, aiming to enhance our understanding and treatment of dual diagnosis. The journal's commitment to addressing the complexities of dual disorders not only informs research but also shapes policy and clinical guidelines, making it an essential read for anyone involved in these critical areas of mental health.